Structure-based MedChem Contract Research (FTE-full time equivalent model)
With its affiliate AliX Pharma, Novalyst offers integrated services for protein structure-based drug discovery. The protein structure–based approach relies on the knowledge of 3D structure of proteins and their interaction with potential drugs.
AliX is specialized in protein structure determination by X-Ray crystallography and provides an innovative ligand screening platform using non-covalent mass spectrometry.
AliX uses its MS-platform to identify hits or fragments, and then Novalyst optimizes these compounds into potential drug candidate using its medicinal chemistry capabilities along with the crystallography and MS-screening platforms.
Structure-based medicinal chemistry services include :
fragment-based in silico screening
ligand- and structure-based virtual screening
hit validation using the innovative MS-screening platform
X-ray crystallography
lead optimization
supported by the classical medicinal chemistry approach.
This integrated offer is proposed on a FTE contract base.